Earlier this month, Cleveland-based RSB Spine announced a 229-percent increase for the third quarter of 2010 versus the third quarter of a year earlier. The medical device company also recently completed a $1.5 million private offering to grow its operations in the United States.

RSB Spine's InterPlate C-Ti has become the first inter-body fusion device to be cleared as an anterior cervical plate. The device is implanted during spinal fusion surgery, holding the vertebrae together while increasing stability. The clearance from the U.S. Food and Drug Administration (FDA) means that the C-Ti can function either as an inter-body device or as a cervical plate.

"[The InterPlate C-Ti] has the advantages of both without the drawbacks of either, so this indication is appropriate," says RSB Spine CEO John A. Redmond.

The InterPlate C-Ti is made of titanium and is used in conjunction with grafting material to fuse two vertebral bodies. When the FDA reclassified inter-body fusion devices in 2007, the C-Ti from RSB Spine was the first device to receive clearance under the new guidelines. With this new clearance, the C-Ti shows its versatility in the treatment of degenerative disc disease.

RSB Spine has more than 150 independent distributors in the United States.



Source: John A. Redmond
Writer: Diane DiPiero